Wharton Sean, Haase Christiane L, Kamran Elham, Liu Aiden, Mancini Johanna, Neish Drew, Pakseresht Arash, Power G Sarah, Christensen Rebecca Ag
Wharton Medical Clinic Burlington ON Canada.
Novo Nordisk A/S Copenhagen Denmark.
Obes Sci Pract. 2020 Apr 15;6(4):382-389. doi: 10.1002/osp4.419. eCollection 2020 Aug.
Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de-identified medical records of 311 patients is the first real-world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight loss.
Overall persistence was assessed, as well as associations of enrollment in SaxendaCare®, persistence and weight loss.
Overall mean (standard deviation) persistence with liraglutide 3.0 mg was 6.3 (4.1) months, and 67.5% ( = 210) and 53.7% ( = 167) of patients persisted for ≥4 and ≥ 6 months, respectively. Enrollment in SaxendaCare® was associated with significantly longer persistence with liraglutide 3.0 mg and greater weight loss. Patients enrolled in SaxendaCare® ( = 119) persisted for 7.9 (4.0) versus 5.2 (3.8) months for those not enrolled ( = 184) ( < 0.001), and had significantly greater percent weight loss after 6 months regardless of the duration of their persistence (-7.9% vs -5.5% from baseline, < 0.01).
These findings suggest that, in clinical settings, persistence with liraglutide 3.0 mg can exceed 6 months, and that enrolling in SaxendaCare® may be associated with comparatively longer persistence and, regardless of persistence, greater weight loss.
如果患者坚持治疗，体重管理药物可显著增加患者实现具有临床意义的体重减轻的机会。这项对311名患者的去识别化医疗记录进行的回顾性观察研究，是加拿大第一项关于3.0毫克利拉鲁肽治疗持续性的真实世界研究，同时还调查了SaxendaCare®患者支持项目与治疗持续性及体重减轻之间的关联。
评估总体治疗持续性，以及参与SaxendaCare®项目、治疗持续性和体重减轻之间的关联。
3.0毫克利拉鲁肽的总体平均（标准差）治疗持续时间为6.3（4.1）个月，分别有67.5%（n = 210）和53.7%（n = 167）的患者持续治疗≥4个月和≥6个月。参与SaxendaCare®项目与3.0毫克利拉鲁肽更长的治疗持续性和更大的体重减轻相关。参与SaxendaCare®项目的患者（n = 119）持续治疗7.9（4.0）个月，而未参与的患者（n = 184）为5.2（3.8）个月（P < 0.001），并且无论治疗持续时间如何，6个月后体重减轻百分比显著更高（与基线相比为-7.9% vs -5.5%，P < 0.01）。
这些发现表明，在临床环境中，3.0毫克利拉鲁肽的治疗持续性可超过6个月，并且参与SaxendaCare®项目可能与相对更长的治疗持续性相关，并且无论治疗持续性如何，体重减轻幅度更大。
